ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Tristan Gicquel
Matched on ORCID iD 0000-0002-0328-493X; OpenAlex author ID A5083724352. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 6
- Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer. Co-author DOI 10.1038/s41389-025-00591-0↗
- Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model. Co-author DOI 10.7554/elife.93312↗
- Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. Co-author DOI 10.1016/j.isci.2023.106899↗
- Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. First author DOI 10.15252/embj.2021110466↗
- Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. Co-author DOI 10.1016/j.xcrm.2020.100143↗
- Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Co-author DOI 10.1038/ncomms16031↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gabriela Reyes‐Castellanos · 4 shared papers, 2020–2025 · strength 0.71
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model. DOI 10.7554/elife.93312↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Alice Carrier · 4 shared papers, 2020–2025 · strength 0.71
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model. DOI 10.7554/elife.93312↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Juan Iovanna · 5 shared papers, 2017–2025 · strength 0.65
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. DOI 10.15252/embj.2021110466↗
- Nadine Abdel Hadi · 3 shared papers, 2020–2025 · strength 0.48
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Rawand Masoud · 3 shared papers, 2020–2025 · strength 0.48
- Paper Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic can… DOI 10.1038/s41389-025-00591-0↗
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Nelson Dusetti · 3 shared papers, 2020–2023 · strength 0.35
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. DOI 10.15252/embj.2021110466↗
- Paper Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. DOI 10.1016/j.xcrm.2020.100143↗
- Fabienne Guillaumond · 3 shared papers, 2017–2023 · strength 0.32
- Paper Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. DOI 10.1016/j.isci.2023.106899↗
- Paper Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. DOI 10.15252/embj.2021110466↗
- Paper Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. DOI 10.1038/ncomms16031↗
- Odile Gayet · 2 shared papers, 2020–2023 · strength 0.24
- Abdessamad El Kaoutari · 2 shared papers, 2020–2023 · strength 0.24
- Sophie Vasseur · 2 shared papers, 2017–2022 · strength 0.17
- Victoire Gouirand · 2 shared papers, 2017–2022 · strength 0.17
- Jared R. Mayers · 2 shared papers, 2017–2022 · strength 0.17
- Richard Tomasini · 2 shared papers, 2017–2022 · strength 0.17
- Matthew G. Vander Heiden · 2 shared papers, 2017–2022 · strength 0.17
- Evan Chen Lien · 1 shared paper, 2022 · strength 0.11
- François Bertucci · 1 shared paper, 2022 · strength 0.11
- Emilie Jaune · 1 shared paper, 2022 · strength 0.11
- Julie Leca · 1 shared paper, 2022 · strength 0.11
- Jérémy Nigri · 1 shared paper, 2022 · strength 0.11
- Véronique Secq · 1 shared paper, 2017 · strength 0.05
- Julie Roques · 1 shared paper, 2017 · strength 0.05
- Dominique Lombardo · 1 shared paper, 2017 · strength 0.05
- Orianne Olivares · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.